Arecor granted patents in India and the United States protecting proprietary formulations of differentiated biopharmaceutical products
Patents further strengthen Group’s extensive patent portfolio protecting its proprietary diabetes portfolio and demonstrate potential of innovative Arestat™ technology in development of enhanced formulations of high value biologics
Arecor announces publication of phase 1 data for AT278 in diabetes care
Ultra-concentrated, ultra-rapid acting insulin AT278, a promising candidate in the pursuit of next generation insulins to simplify and improve glycemic control
Arecor announces transfer of AT307 to Hikma
License milestone to develop and commercialise ready-to-use medicine achieved. Arecor regains rights to AT282 following portfolio review at Hikma.
Arecor granted key patent In Japan and South Korea to protect proprietary insulin products At247 and At278
The granted patents further strengthen the Group’s extensive patent portfolio protecting its proprietary Arestat™ technology and diabetes product portfolio
Arecor to commence second clinical trial with at278 ultra-concentrated ultra-rapid acting insulin candidate for type 2 diabetes
Clinical trial application approved - EU Phase I clinical trial expected to commence in December 2022
Arecor announces exclusive specialty hospital formulation collaboration
Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, today announces that it has signed an exclusive formulation study collaboration with the pharmaceutical division of one of the world’s largest chemicals marketing and pharmaceut
Arecor announces exclusive specialty hospital formulation collaboration
Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, today announces that it has signed an exclusive formulation study collaboration with the pharmaceutical division of one of the world’s largest chemicals marketing and pharmaceuticals companies, which focuses on the development and commercialisation of speciality drugs.
New headline results from Phase I clinical trial of ultra-rapid acting insulin candidate AT247
Cambridge UK - Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces headline results from the second Phase I clinical trial of its ultra-rapid acting insulin, AT247, which support its potential to facilitate a fully closed loop artificial pancreas.
Arecor granted european patents protecting proprietary formulations of high concentration Humira® Biosimilar
Cambridge, UK - Arecor Therapeutics plc, the biopharmaceutical group advancing today’s therapies to enable healthier lives, is pleased to announce that the European Patent Office has granted two patents (EP3592383B1 and EP3592385B1) protecting the Group’s novel formulations of high-concentration adalimumab until 2038.
Arecor announces presentation at EASD 2022 of Phase I clinical trial of AT278 ultra-concentrated ultra-rapid acting insulin for diabetes
Arecor Therapeutics plc, a globally focused biopharmaceutical company advancing today’s therapies to enable healthier lives, announces that its abstract titled “Phase I study investigating PK and PD of highly-concentrated insulin aspart AT278 U500” has been selected for presentation as part of the Short Oral Discussion Session A at the 58th Annual Meeting of the European Association for the Study…
Arecor announces exclusive collaboration with a top 5 global pharmaceutical company
Cambridge, UK - Arecor Therapeutics plc, the biopharmaceutical group advancing today’s therapies to enable healthier lives, announces that it has signed an exclusive formulation study collaboration with a top five global pharmaceutical company.
Arecor presents full data from positive phase I clinical trial of AT278 ultra-concentrated ultra-rapid acting insulin for diabetes
Arecor Therapeutics plc, the biopharmaceutical company advancing today’s therapies to enable healthier lives, presents positive results from the Phase I clinical trial of its ultra-rapid acting, ultra-concentrated insulin product candidate, AT278, at the 15th International Advanced Technologies and Treatments for Diabetes (ATTD) meeting. The abstract is available on the ATTD website.
Arecor announces oral presentation at Attd 2022
Arecor announces oral presentation at attd 2022 of phase 1 clinical trial of at278 ultra-concentrated ultra-rapid acting, insulin for diabetes.
Arecor granted key U.S. patent protecting proprietary insulin products
Further strengthens the Company’s extensive patent portfolio protecting its proprietary Arestat™ technology and diabetes product portfolio.
Arecor commences US Phase I clinical trial of AT247 ultra-rapid insulin in combination with an insulin pump
First patient dosed in potential game-changing diabetes combination therapy.
Arecor announces exclusive collaboration with global technology leader
Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, today announces that it has signed an exclusive formulation study collaboration.
Arecor granted key Canadian patent for proprietary technology enabling highly concentrated biotherapeutics
Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, continues to build a strong patent portfolio protecting its proprietary Arestat™ technology.
Arecor announces exclusive collaboration with leading global medical products company
Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, today announces that it has signed an exclusive formulation study collaboration with a leading global medical products company.
Arecor’s polysaccharide vaccine patent upheld
Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, continues to build a strong patent portfolio protecting its proprietary Arestat™ technology. Arecor is pleased to announce that its European patent EP2457590 on polysaccharide vaccines has been successfully upheld following opposition appeal proceedings filed by GlaxoSmithKline…
Arecor announces positive headline results from first Phase I clinical trial of diabetes treatment
Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that its ultra-concentrated ultra-rapid acting insulin, AT278 met all of its primary and secondary endpoints with positive headline results from the Phase I clinical trial.
Arecor announces FDA clearance of Investigational New Drug application for diabetes treatment
Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, today announces US Food and Drug Administration (FDA) clearance of the Group’s Investigational New Drug (IND) application for AT247, the Group’s proprietary wholly owned ultra-rapid insulin for the treatment of diabetes.
Arecor signs exclusive formulation collaboration with Intas Pharmaceuticals
Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing therapies to enable healthier lives, today announces that it has signed a formulation agreement with Intas Pharmaceuticals Ltd.
Arecor announces appointment of Grant Thornton as auditor
Arecor Therapeutics plc (AIM: AREC), a globally focused biopharmaceutical group advancing today’s therapies to enable healthier lives, announces that Grant Thornton UK LLP has been appointed as the Group’s auditor, with immediate effect. Lakin Rose Limited has resigned as the auditor of Arecor Limited.
Arecor appoints Dr Lindsey Foulkes as Chief Operating Officer
Arecor Therapeutics plc (AIM: AREC), a globally focused biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces the appointment of Dr Lindsey Foulkes as the company’s Chief Operating Officer.
Arecor announces exclusive formulation study collaboration with Par
Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that it has signed a formulation study agreement with Par Sterile Products, LLC, an Endo International plc company (Par).